Drug Trial Radar · NCT07578116
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
562
Planned (sponsor's estimate)
Start
Mar 9, 2027
Primary completion
May 31, 2032
Study completion May 31, 2033
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic HER2-Positive Breast Carcinoma
- Oligometastatic Breast Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Breast Conservation TreatmentProcedure
Undergo breast conserving therapy
Computed TomographyProcedure
Undergo CT and/or PET/CT
Cyclin-Dependent Kinase 4 InhibitorDrug
Given CDK4/6 inhibitor
Cyclin-Dependent Kinase 6 InhibitorDrug
Given CDK4/6 inhibitor
Echocardiography TestProcedure
Undergo ECHO
HER2-targeted TherapyDrug
Receive HER2-targeted systemic therapy
Hormone TherapyDrug
Given endocrine therapy
Magnetic Resonance ImagingProcedure
Undergo MRI
MammographyProcedure
Undergo mammography
PertuzumabBiological
Given pertuzumab
Positron Emission TomographyProcedure
Undergo PET/CT
Radiation BoostRadiation
Undergo RT boost
Radiation TherapyRadiation
Undergo RT
Stereotactic Body Radiation TherapyRadiation
Undergo SBRT
Stereotactic RadiosurgeryRadiation
Undergo SRS/SRT
Taxane CompoundDrug
Given taxane therapy
Total MastectomyProcedure
Undergo total mastectomy
TrastuzumabBiological
Given trastuzumab
Trastuzumab DeruxtecanBiological
Given T-DXd
Trastuzumab EmtansineBiological
Given T-DM1
Ultrasound ImagingProcedure
Undergo ultrasound
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) (Cohort A)Time frame: From date of Step 2 registration to date of death, assessed up to 10 years
- Progression-free survival (PFS) (Observational Cohort B)Time frame: From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years
- Overall survival (Observational Cohort B)Time frame: From date of Step 2 registration to date of death, assessed at 3 and 5 years
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut · Recruiting
Smilow Cancer Hospital-Hamden Care Center
Hamden, Connecticut · Recruiting
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut · Recruiting
Smilow Cancer Hospital-Torrington Care Center
Torrington, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
Smilow Cancer Hospital-Waterbury Care Center
Waterbury, Connecticut · Recruiting
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
OSF Saint Joseph Medical Center
Bloomington, Illinois · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois · Recruiting
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois · Recruiting
Illinois CancerCare-Macomb
Macomb, Illinois · Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois · Recruiting
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois · Recruiting
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois · Recruiting
Illinois CancerCare-Pekin
Pekin, Illinois · Recruiting
Illinois CancerCare-Peoria
Peoria, Illinois · Recruiting
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois · Recruiting
OSF Saint Francis Medical Center
Peoria, Illinois · Recruiting
Illinois CancerCare-Peru
Peru, Illinois · Recruiting
Illinois CancerCare-Princeton
Princeton, Illinois · Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Springfield Memorial Hospital
Springfield, Illinois · Recruiting
Illinois CancerCare - Washington
Washington, Illinois · Recruiting
Mercy Cancer Center-West Lakes
Clive, Iowa · Recruiting
Iowa Methodist Medical Center
Des Moines, Iowa · Recruiting
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.